Healthcare
Live Price
Offline$84.32
-1.30% today
1Y Change
+58.32%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sandoz Group AG (SDZNY) is a Healthcare stock with a market cap of $34.60B and listed on OTC. The stock last traded around $84.32 and up 58.3% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -14.9%, EPS growth of 0.0%, a dividend yield of 1.3%. What stands out right now is revenue -14.9%, EPS 0.0%, free cash flow +1250.0% with operating margin 14.6% and ROIC 7.8%. The dividend is present but secondary, with a yield around 1.3%. Valuation already assumes a fairly strong business story at P/E 37.5 and price/sales 3.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SDZNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SDZNY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SDZNY Max Drawdown
-19.09%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SDZNY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.8B
+2.2% YoY
FY Net Income
$830.2M
+5.9% YoY
Free Cash Flow
$855.8M
+12.6% YoY
Revenue Growth
-14.9%
EPS Growth
+0.0%
Gross Margin
47.2%
Net Margin
8.2%
Income statement
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 8.8B | 10.4B | 10.0B | 8.6B | 8.8B |
| Gross Profit | 4.2B | 4.9B | 4.6B | 4.0B | 4.2B |
| Operating Income | 1.4B | 307M | 375M | 1.1B | 1.4B |
| EBITDA | 1.4B | 742M | 857M | 1.5B | 1.7B |
| Net Income | 729M | 1M | 77M | 784M | 830M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.7B | 1.2B | 1.1B | 74M | 36M |
| Total Assets | 22.0B | 19.9B | 19.4B | 16.2B | 16.0B |
| Total Liabilities | 12.6B | 11.7B | 10.8B | 23K | 8.5B |
| Shareholder Equity | 9.4B | 8.2B | 8.6B | 77K | 7.4B |
| Total Debt | 5.7B | 4.9B | 4.6B | 3.9B | 4.5B |
| Net Debt | 3.9B | 3.7B | 3.4B | 3.8B | 248M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.2B
+6.0% YoY
Capital Expenditures
382M
+6.3% YoY
Free Cash Flow
856M
+12.6% YoY
Key ratios
Gross Margin
47.2%
Operating Margin
14.6%
Net Margin
8.2%
ROE
10.1%
Debt / Equity
0.61x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.